# A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer

Source: https://onco.cc/trials/nct07446387/  
OnCo record `nct07446387` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Iparomlimab and tuvonralimab in Colorectal cancer, run by Jiangsu Cancer Institute & Hospital, not yet recruiting.

## Summary

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer is a phase 2 interventional study registered as NCT07446387 by Jiangsu Cancer Institute & Hospital, with 70 participants planned, started 2026-05-30 and due to reach its primary completion in 2028-12-31. Interventions recorded: Iparomlimab and tuvonralimab. Conditions recorded: Metastatic Colorectal Cancer (CRC).

Linked to the drug Iparomlimab and tuvonralimab because the registry names it among its interventions and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07446387
- Phase: 2
- Setting: A Prospective, Single-arm, Multicenter Phase II Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer
- Sponsor: Jiangsu Cancer Institute & Hospital
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT07446387: https://clinicaltrials.gov/study/NCT07446387

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Iparomlimab and tuvonralimab](https://onco.cc/drugs/iparomlimab-tuvonralimab/)

---
JSON: https://onco.cc/api/v1/entities/nct07446387.json